Reduced-Dose JAK Inhibitors Maintain Persistence in Low-Risk Rheumatoid Arthritis

Janus kinase inhibitors have expanded the therapeutic landscape for moderate to severe rheumatoid arthritis, offering efficacy comparable to biological disease-modifying antirheumatic drugs [1]. While these agents significantly improve patient-reported outcomes and disease activity, clinical adoption is often tempered by concerns regarding dose-dependent adverse events, particularly venous thromboembolism and serious infections [2, 3]. Current evidence suggests that while higher doses do not always provide incremental clinical benefits, they may increase the risk of specific cardiovascular complications [4]. Consequently, many clinicians explore dose reduction strategies in stable patients to balance long-term safety with the maintenance of clinical remission [5]. To guide these everyday prescribing decisions, a new multicenter registry study examines how initial dosing strategies influence long-term drug retention, a key marker of both efficacy and tolerability, across different patient risk profiles.